|
THE IMAGES AND LINKS ABOVE ARE FROM THE INITIAL PROTOTYPE SYSTEM Delphinus Medical Technologies, Inc., is a Michigan-based company that is in the final stages of developing a three-dimensional full-breast ultrasound imaging device that uses a safe (non-ionizing), comfortable (non-compressing), and reliable (operator independent) patented technology. Delphinus has an initial prototype system installed at the Barbara Ann Karmanos Cancer Institute and has run clinical studies on nearly 500 patients ranging from breast cancer diagnosis, therpay monitoring and breast cancer risk assessment. The new system that is currently in development is incorporating the learnings from these studies and will result in a faster and higher sensitivity system that will be commercialized following approval by the Food and Drug Administration. News: January 19, 2011 - Michigan Governor Rick Snyder salutes Dr. Littrup and SoftVue/Delphinus team at State of the State address October 29, 2010 - Delphinus receives grant from the IRS under the Qualifying Therapeutic Discover Project Program. September 2010 - Delphinus receives an additional $1.5 million cash investment from the original VC consortium. July 20, 2010 - Delphinus receives $779,118 in tax incentives from the Michigan Economic Growth Authority. May 25, 2010 - Karmanos Cancer Institute's Delphinus receives $8 million in venture capital for product development of breast cancer imaging tool.
"SoftVue is currently under development and has not received clearance from the FDA at this time"
|
|
